About
Here you will find summaries of all the latest publications on lupus, focusing on those covering treatments, recommendations and other topics that may influence clinical practice.
Latest Updates
All ▼
Lupus low disease activity state and organ damage in relation to quality of life in systemic lupus erythematosus: A cohort study with up to 11 years of follow-up
CD19 CAR T-Cell therapy in autoimmune disease - A case series with follow-up
Evaluation of RNase Therapy in Systemic Lupus Erythematosus: A Randomised Phase 2a Clinical Trial of RSLV-132
Smith-specific regulatory T cells halt the progression of lupus nephritis
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: A multicentre, open-label, randomised controlled trial
Development of the American College of Rheumatology's Patient-reported Outcome Quality Measures for Systemic Lupus Erythematosus
Predictors of Renal Flares in Systemic Lupus Erythematosus: A Post-hoc Analysis of Four Phase III Clinical Trials of Belimumab
Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort
Kidney Outcomes and Preservation of Kidney Function with Obinutuzumab in Patients with Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial
Efficacy and Safety of Telitacicept in Patients with Systemic Lupus Erythematosus: A Multicentre, Retrospective, Real-World Study
Telitacicept in Patients with Active Systemic Lupus Erythematosus: Results of A Phase 2b, Randomised, Double-blind, Placebo-controlled Trial
Burden of Systemic Lupus Erythematosus in Clinical Practice: Baseline Data from the SLE Prospective Observational Cohort Study (SPOCS) by Interferon Gene Signature
Assessment and Personalised Advice for Fatigue in Systemic Lupus Erythematosus Using an Innovative Digital Tool: The Lupus Expert System for the Assessment of Fatigue (LEAF) Study
Emerging Immunotherapeutic Strategies for Cutaneous Lupus Erythematosus: An Overview of Recent Phase 2 and 3 Clinical Trials
EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update
Impact of Low Disease Activity, Remission, and Complete Remission on Flares Following Tapering of Corticosteroids and Immunosuppressive Therapy in Patients with Systemic Lupus Erythematous: A Multinational Cohort Study
Repeat Kidney Biopsy Findings of Lupus Nephritis Patients in Clinical Remission Treated with Mycophenolate Associated with Belimumab or Mycophenolate Plus Standard of Care Therapy. A “Post-hoc" Analysis of Participants in the BLISS-LN and Open Label Extension Study Belonging to a Single Center
Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune Diseases
Effect of Belimumab on Kidney-related Outcomes in Patients with Lupus Nephritis: Post Hoc Subgroup Analyses of the Phase 3 BLISS-LN Trial
SGLT2 Inhibitors Alleviated Podocyte Damage in Lupus Nephritis by Decreasing Inflammation and Enhancing Autophagy
Safety and Efficacy of Long-term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial
Health Related Quality of Life, Remission and Low Lupus Disease Activity State in Patients with Systemic Lupus Erythematosus
Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis
Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
Risk and Factors Associated with Disease Manifestations in Systemic Lupus Erythematosus - Lupus Nephritis (RIFLE-LN): A Ten-year Risk Prediction Strategy Derived from a Cohort of 1652 Patients
Early Infection Risk in Patients with Systemic Lupus Erythematosus Treated with Rituximab or Belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): A Prospective Longitudinal Study
Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process with RISE Registry Data Review
Belimumab Versus Anifrolumab in Adults with Systemic Lupus Erythematosus: An Indirect Comparison of Clinical Response at 52 Weeks
Machine Learning Identifies Clusters of Longitudinal Autoantibody Profiles Predictive of Systemic Lupus Erythematosus Disease Outcomes
Litifilimab (BIIB059), a Promising Investigational Drug for Cutaneous Lupus Erythematosus
Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials
